What medications do physicians prescribe for androgenic alopecia?

Treatment for Androgenic Alopecia

For men with androgenic alopecia, prescribe oral finasteride 1 mg daily or oral dutasteride 0.5 mg daily combined with topical minoxidil 5% twice daily; for women, prescribe topical minoxidil 1% twice daily as first-line therapy, with low-dose oral minoxidil (LDOM) emerging as an effective alternative when topical formulations are not tolerated. 1

First-Line Treatments by Sex

For Men

The evidence-based approach prioritizes:

• Oral finasteride 1 mg daily - First-line androgen-targeting therapy 1
• Oral dutasteride 0.5 mg daily - Alternative first-line option 1
• Topical minoxidil 5% twice daily - FDA-approved, can be used alone or combined with finasteride/dutasteride 2, 1

These medications work through different mechanisms: finasteride and dutasteride reduce dihydrotestosterone (DHT) levels by inhibiting 5-α-reductase, while minoxidil promotes hair growth through vasodilation and follicular stimulation 3.

For Women

The treatment algorithm differs significantly:

• Topical minoxidil 1% twice daily - Only FDA-approved first-line option 1
• Topical minoxidil 5% foam once daily - Alternative FDA-approved regimen 2
• Oral finasteride and dutasteride are contraindicated in women of childbearing potential 1

Emerging Alternative: Low-Dose Oral Minoxidil (LDOM)

LDOM represents a significant advancement supported by 2025 international consensus guidelines 2. This off-label use addresses common limitations of topical formulations including:

• Contact dermatitis from propylene glycol
• Poor adherence due to application inconvenience
• Inadequate scalp coverage

LDOM Prescribing Protocol

Based on the most recent consensus 2, 4:

Baseline evaluation before initiating:

• Blood pressure and pulse measurement
• Medical history screening for contraindications (pregnancy, breastfeeding, cardiac disease)
• Discussion of dose-related side effects

Dosing strategy:

• Start at low doses (specific starting doses determined by baseline BP and medical history)
• Titrate based on tolerance and side effect profile
• Effects are dose-dependent, allowing individualized optimization

Monitoring requirements:

• BP and pulse checks before and 2 hours after new dose initiation 4
• Assessment at 2-4 months for fluid retention (pedal edema, periorbital swelling, weight gain)
• Evaluation at 2-4 months for hypertrichosis (facial/body hair growth)

Critical LDOM Side Effects to Counsel Patients About

Immediate concerns (within hours):

• Hypotension causing dizziness or lightheadedness - stop medication and contact physician
• Chest pain - stop medication and seek emergency care immediately 4

Delayed concerns (2-4 months):

• Fluid retention requiring diuretic therapy or dose reduction
• Hypertrichosis manageable with local hair removal or antiandrogens 4

Initial shedding (4-6 weeks):

• Temporary increased hair loss is a positive sign indicating follicular synchronization 4

Rare but serious:

• Pericardial effusion (fluid around heart) - though recent controlled trial showed similar 6% prevalence in treated and untreated patients 4

Second-Line and Adjunctive Options

When first-line therapies fail or are contraindicated 1:

• Low-level laser therapy (LLLT) - FDA-cleared for AGA
• Platelet-rich plasma (PRP) - Procedural option with growing evidence 5
• Hair transplantation - Surgical option for advanced cases
• Topical adenosine - Recommended for male pattern hair loss 1

Critical Pitfalls to Avoid

Do not prescribe oral finasteride or dutasteride to women of childbearing potential - these are pregnancy category contraindications due to teratogenic effects 1.

Do not dismiss LDOM due to its antihypertensive origins - the doses used for hair loss are substantially lower than antihypertensive doses (10-40 mg daily), making the safety profile distinct 2.

Do not fail to warn about initial shedding - patients starting minoxidil (topical or oral) experience temporary increased shedding at 4-6 weeks, which paradoxically indicates treatment response 4.

Do not overlook topical minoxidil contact dermatitis - this is usually due to propylene glycol in formulations, not minoxidil itself, and switching to foam formulations or LDOM can resolve this 2.